HealthTree Logo
search more_vert
close
person Sign In / Create Account
The Role Of Maintenance Therapy after SCT
The Role Of Maintenance Therapy after SCT image
Stem Cell Transplant
event Aug 31, 2022 / 01:00PM - 02:00PM EDT

Event Description

Why is maintenance therapy so strongly recommended after a stem cell transplant? How long do physicians wait to give maintenance therapy after the procedure? For how long is the maintenance therapy given? Learn the answers to these questions and more as we meet with Dr. Samuel Rubinstein who will share with us his professional opinion. 

Schedule & Agenda

The panelist Audrey Burton-Bethke
Introduction
01:00PM
Audrey Burton-Bethke
Audrey introduces the agenda of the event and featured speaker Dr. Samuel Rubinstein
The panelist Dr. Samuel Rubinstein
Presentation
01:05PM
Dr. Samuel Rubinstein
Dr. Samuel Rubinstein shares his professional opinion on the role of maintenance therapy after stem cell transplant.
The panelist Audience
Questions and Answers
01:35PM
Audience
Type your questions in the chat and we will answer them!

Speakers & Moderators

The panelist Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio
The panelist Dr. Samuel Rubinstein
Dr. Samuel Rubinstein

Dr. Rubinstein is an assistant professor and malignant hematologist at the University of North Carolina Chapel Hill and an associate member of the Lineberger Comprehensive Cancer Center. His primary clinical and research area of interest is plasma cell dyscrasias, and he is focused on clinical trials designed to improve the standard of care of patients with these disorders. In addition to clinical trials, Dr. Rubinstein has an informatics background, which he has leveraged to develop multiple prognostic scoring tools that are useful in the management of patients with plasma cell dyscrasias. During the COVID-19 pandemic, Dr. Rubinstein also developed an interest in the impacts of COVID-19 on patients with cancer. He serves as the site PI of the COVID-19 and cancer consortium (CCC19) at UNC, and in this capacity has contributed to a number of studies derived from CCC-19 data to answer clinically relevant questions about the epidemiology and outcomes of patients with cancer and COVID-19.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
GSK
Regeneron
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube